What is my patient’s prognosis with metastatic prostate cancer?

Estimate overall survival specifically in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) starting a first-line AR-pathway inhibitor (e.g., enzalutamide) using clinical and laboratory features to support prognostic discussions and treatment planning. Not intended for broader metastatic or hormone-sensitive disease.